| IGHV SHMlow | IGHV SHMhigh | P | IGK/LV SHMlow | IGK/LV SHMhigh | P |
---|
n (%) | n (%) | n (%) | n (%) |
---|
Age |
< 60 years | 32 (44%) | 25 (36%) | .31 | 66 (40%) | 14 (37%) | .72 |
≥ 60 years | 40 (56%) | 45 (64%) | | 97 (60%) | 24 (63%) | |
Sex |
Male | 35 (49%) | 41 (59%) | .24 | 94 (58%) | 26 (68%) | .27 |
Female | 37 (51%) | 29 (41%) | | 69 (42%) | 12 (32%) | |
Stage |
I - II | 29 (43%) | 34 (52%) | .39 | 72 (46%) | 14 (39%) | .58 |
III - IV | 39 (57%) | 32 (48%) | | 86 (54%) | 22 (61%) | |
B symptoms |
No | 38 (56%) | 43 (63%) | .48 | 103 (66%) | 28 (78%) | .23 |
Yes | 30 (44%) | 25 (37%) | | 53 (34%) | 8 (22%) | |
Serum LDH level |
Normal | 21 (33%) | 29 (45%) | .20 | 67 (46%) | 18 (55%) | .44 |
Elevated | 43 (67%) | 35 (55%) | | 78 (54%) | 15 (45%) | |
No. of extranodal sites |
0 or 1 | 51 (76%) | 53 (82%) | .53 | 126 (81%) | 26 (70%) | .18 |
≥ 2 | 16 (24%) | 12 (18%) | | 30 (19%) | 11 (30%) | |
ECOG performance status |
0 or 1 | 47 (80%) | 44 (76%) | .66 | 113 (79%) | 26 (81%) | 1.0 |
≥ 2 | 12 (20%) | 14 (24%) | | 30 (21%) | 6 (19%) | |
Largest tumor size |
< 5 cm | 37 (66%) | 27 (53%) | .17 | 73 (57%) | 13 (43%) | .22 |
≥ 5 cm | 19 (34%) | 24 (47%) | | 55 (43%) | 17 (57%) | |
IPI score |
0–2 | 40 (60%) | 42 (64%) | .72 | 97 (62%) | 21 (57%) | .58 |
3–5 | 27 (40%) | 24 (36%) | | 60 (38%) | 16 (43%) | |
Therapy response |
CR | 51 (71%) | 54 (77%) | .45* | 126 (77%) | 27 (73%) | .67* |
PR | 10 | 8 | | 21 | 3 | |
SD | 2 | 3 | | 4 | 1 | |
PD | 9 | 5 | | 12 | 6 | |
ABC subtype/ABC subtype |
GCB | 27 (39%) | 39 (53%) | .094 | 78 (47%) | 21 (57%) | .36 |
ABC | 43 (61%) | 34 (47%) | | 88 (53%) | 16 (43%) | |
BAGS classification |
CC/CB | 24 (52%) | 40 (75%) | .02 | 77 (64%) | 21 (81%) | .11 |
Others | 22 (48%) | 13 (25%) | | 43 (36%) | 5 (19%) | |
BCL2 translocation |
No | 55 (87%) | 46 (72%) | .047 | 125 (81%) | 22 (65%) | .042 |
Yes | 8 (13%) | 18 (28%) | | 29 (19%) | 12 (35%) | |
MYC expression |
< 70% | 39 (57%) | 50 (72%) | .047 | 117 (72%) | 26 (68%) | .69 |
≥ 70% | 29 (43%) | 19 (28%) | | 46 (28%) | 12 (32%) | |
PI3K expression |
< 70% | 43 (67%) | 50 (75%) | .44 | 112 (72%) | 14 (42%) | .0018 |
≥ 70% | 21 (33%) | 17 (25%) | | 43 (28%) | 19 (58%) | |
p63 expression |
< 10% | 47 (68%) | 38 (54%) | .086 | 93 (59%) | 14 (39%) | .04 |
≥ 10% | 22 (32%) | 33 (46%) | | 65 (41%) | 22 (61%) | |
CD30 expression |
< 20% | 58 (83%) | 60 (83%) | 1.0 | 135 (82%) | 37 (97%) | .012 |
≥ 20% | 12 (17%) | 12 (17%) | | 30 (18%) | 1 (3%) | |
p65 expression |
< 10% | 22 (35%) | 29 (43%) | .47 | 61 (41%) | 7 (21%) | .031 |
≥ 10% | 40 (65%) | 39 (57%) | | 89 (59%) | 27 (79%) | |
CXCR4 expression |
< 20% | 43 (73%) | 47 (70%) | .84 | 109 (72%) | 19 (53%) | .029 |
≥ 20% | 16 (27%) | 20 (30%) | | 42 (28%) | 17 (47%) | |
- Abbreviations: IGHV Immunoglobulin heavy chain variable region gene, IGK/LV Immunoglobulin kappa or lambda light chain variable region gene, SHMlow Low degree of somatic hypermutation, SHMhigh High degree of somatic hypermutation, LDH Lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, GCB germinal center B-cell–like, ABC Activated B-cell–like, BAGS B-cell–associated gene signature, CB Centroblast subtype, CC Centrocyte subtype
- Note: Not all patients had data available. Significant P values (Fisher’s exact test) are in bold. *For therapy response, P values were for comparisons between CR and non-CR cases